New sedative aims to calm ICU patients safely

NCT ID NCT06222294

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested a sedative called remimazolam tosilate in 214 ICU patients who were on breathing machines. The goal was to see if it works as well as or better than the standard sedative propofol. Patients received either remimazolam or propofol, and researchers measured how often they stayed at the right sedation level without needing extra medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

remimazolam tosilate

What this could lead to

If successful, this could offer a safer sedation option for ICU patients on breathing machines.

What could go wrong

This is a completed Phase 3 trial, but results are not yet published. Remimazolam may not be more effective or safer than current sedatives like propofol.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEDATION IN THE ICU are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, 510080, China